Elesclomol (STA-4783)

Catalog No.S1052

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Cited by 6 Publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665

BMC Genomics, 2014, 15(1):263

PubMed: 24708151

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766

2 Customer Reviews

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MmO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1T3SmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh\|ryP	NXvENFl7W0GQR1XS
CAL-51 cell	Mo\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlTkTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?=	MVjTRW5ITVJ?
ABC-1 cell	NHLrVo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXvJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6zOlUhdk1?	M{\MbXNCVkeHUh?=
A2780 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWnnXlZqUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl2IH7N	NGeyW3VUSU6JRWK=
ES1 cell	NXrGeXdWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1nVPGlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD63OFkhdk1?	M2LOXHNCVkeHUh?=
HUTU-80 cell	M1PDN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYjwdWI1UW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OUGgcm0>	Mn3tV2FPT0WU
NCI-H292 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2=	NXy2XHJ1W0GQR1XS
NB69 cell	M37KUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1rhbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlIhdk1?	NGC2V\|BUSU6JRWK=
ES8 cell	NUPsRpFsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2XTOmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zNkBvVQ>?	M{C0fnNCVkeHUh?=
BCPAP cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVG4PGRLUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2=	NF;td3dUSU6JRWK=
T-24 cell	Mk\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH7reJZKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2KG6P	M4Pj[nNCVkeHUh?=
EW-16 cell	M1;XUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn64TY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlEhdk1?	NXm3coc2W0GQR1XS
OVCAR-5 cell	NV;P[lBwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYOyeJdzUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56MzDuUS=>	M{DuPXNCVkeHUh?=
SF126 cell	MmPSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXvUO\|ZXUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTVibl2=	MnHVV2FPT0WU
KP-4 cell	NFXw[o9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkfVTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xO{BvVQ>?	MYLTRW5ITVJ?
GAMG cell	MmfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnfsTY5pcWKrdHnvckBw\iCqdX3hckBISU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61NUBvVQ>?	M{\wenNCVkeHUh?=
HOS cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIHTd4lKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVMhdk1?	NVTT[4RyW0GQR1XS
CHL-1 cell	Ml\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2TrdGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlgyKG6P	NV7kfVJ6W0GQR1XS
AGS cell	MnmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYfCW2FbUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P	MWDTRW5ITVJ?
MDA-MB-157 cell	MlLzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N	M4DsOHNCVkeHUh?=
HSC-3 cell	NVTZWmdbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnLZTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFIhdk1?	NFPIS3VUSU6JRWK=
CAL-72 cell	NIPnO\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmjwTY5pcWKrdHnvckBw\iCqdX3hckBESUxvN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P	M4jYcHNCVkeHUh?=
NBsusSR cell	M3\WNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnLRTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?=	NX21dGx5W0GQR1XS
ES7 cell	MoLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX3kU2NjUW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlU6KG6P	NUDHNIFuW0GQR1XS
H-EMC-SS cell	NUPwVIdGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYfJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?=	M{jMRnNCVkeHUh?=
NCI-H1703 cell	MmWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmfmTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N	MWnTRW5ITVJ?
BHT-101 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlczKG6P	MWrTRW5ITVJ?
SK-OV-3 cell	M4e1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnrzTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44PSCwTR?=	NX3uWVNsW0GQR1XS
EW-24 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHjCcpNKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OyCwTR?=	M4C5d3NCVkeHUh?=
PSN1 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlTWTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz64OEBvVQ>?	M1rWRXNCVkeHUh?=
OVCAR-8 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3ixc2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2=	MVzTRW5ITVJ?
NCI-H1563 cell	NWf0clA1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NG\NOFZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU3OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMUOgcm0>	Ml;tV2FPT0WU
SW756 cell	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlHRTY5pcWKrdHnvckBw\iCqdX3hckBUXzd3NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVMhdk1?	NVzVXGt2W0GQR1XS
A375 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1LtZWlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVQhdk1?	MkjPV2FPT0WU
Ca9-22 cell	M1T1UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYX2SoJNUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N	NVTJemdpW0GQR1XS
SW1990 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NITWdnRKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUm5NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzJibl2=	MVTTRW5ITVJ?
ES4 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEfXb3dKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|khdk1?	MYLTRW5ITVJ?
HCE-T cell	NXTCcGFCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUTmTFRWUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2=	M1\HUHNCVkeHUh?=
MOLT-16 cell	NHHjXY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P	NH\HUnVUSU6JRWK=
HSC-4 cell	M4XlWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4jV[mlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlghdk1?	MUnTRW5ITVJ?
NCI-SNU-1 cell	MkfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NW\VT3MyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O	NGnTSJFUSU6JRWK=
EW-11 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn36TY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuPUBvVQ>?	MXzTRW5ITVJ?
HT-1080 cell	NXvzU215T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4rIfWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2=	M{jobXNCVkeHUh?=
MES-SA/Dx5 cells	NIf1bllEgXSxdH;4bYNqfHliYYPzZZk>	M{XSTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOsJGlEPTB;NTDuUS=>	NHHmOGUzOzl\|N{m4NS=>
SW1710 cell	M4n0NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXW0fI41UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF4IH7N	MVvTRW5ITVJ?
EW-1 cell	NG\GR\|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3PKW2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuNlQhdk1?	NUjWSItuW0GQR1XS
BV-173 cell	NX3K[\|Z[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MljvTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P	MXHTRW5ITVJ?
TE-8 cell	NHPXclhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1;3TWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFEhdk1?	NWq2dGlmW0GQR1XS
G-401 cell	NVPad21OT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60N{BvVQ>?	M2DUXXNCVkeHUh?=
KOSC-2 cell	NXLwcpVkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXLJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFUhdk1?	MVLTRW5ITVJ?
HuCCT1 cell	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mm\1TY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P	NHXRR4ZUSU6JRWK=
FADU cell	NGq1RplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkDCTY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT62OkBvVQ>?	NXjyR2VTW0GQR1XS
MHH-ES-1 cell	MlvxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH\tSItKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54OTDuUS=>	MXLTRW5ITVJ?
ES3 cell	NIW3dVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHLzVFhKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|khdk1?	M3njVHNCVkeHUh?=
OVCAR-4 cell	M{jQSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{C0[mlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDdibl2=	MnfWV2FPT0WU
HD-MY-Z cell	NEPLbmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWTER5I5UW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57MTDuUS=>	M3n4XXNCVkeHUh?=
human JAR cell	M1zsdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmH3TY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3JI5O	MkOxV2FPT0WU
A427 cell	MnPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2XtfGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNFchdk1?	MXjTRW5ITVJ?
697 cell	NHTkNopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NF;FNm9KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNVMhdk1?	NY\lZXJxW0GQR1XS
OVCAR-3 cell	MoH5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGfJS5RKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJibl2=	MXvTRW5ITVJ?
human NB14 cell	NELBRnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHTxU21KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P	MkPTV2FPT0WU
GB-1 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWLZZ5c3UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?=	NXTKc2tlW0GQR1XS
COR-L105 cell	Mmi4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYXpZ2ZNUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwN{[gcm0>	NXfZU3hrW0GQR1XS
647-V cell	MkXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3r6SmlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1?	Mnr1V2FPT0WU
human K5 cell	Ml3QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVrsZo11UW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUegcm0>	NWXCbVlUW0GQR1XS
DMS-273 cell	NHrnWVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3LU[2lvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUK3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2=	NGT0PHVUSU6JRWK=
UM-UC-3 cell	MlHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnS4TY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?=	NUX6S5FrW0GQR1XS
HEL cell	M1O4Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4foZmlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz6wPEBvVQ>?	NGXYVlFUSU6JRWK=
human KU-19-19 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4C3RWlvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB7IH7N	NY\VVZgyW0GQR1XS
MC-IXC cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYK5PYN7UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjF5IH7N	Mmn0V2FPT0WU
human H4 cell	MnTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1zPOGlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O	NH3JenZUSU6JRWK=
NUGC-3 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlTYTY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P	NX3NXWtbW0GQR1XS
CHP-212 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUm0V2pSUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5\|NDDuUS=>	MYLTRW5ITVJ?
human SW982 cell	NUn4W4JnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEDVO3ZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?=	MnKyV2FPT0WU
C-33-A cell	Mm\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGLYNGlKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPThibl2=	MU\TRW5ITVJ?
PC-3 cell	NFTDTGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXXW[lQ2UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?=	NGOyTVhUSU6JRWK=
COLO-684 cell	NIO4[HlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXviUJBrUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTlwMkGgcm0>	MW\TRW5ITVJ?
SNU-387 cell	M3u0OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NG\idpFKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N	M4fTXHNCVkeHUh?=
U251 cell	M3;5b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGHSWWJKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3KG6P	NXjHV4NUW0GQR1XS
A673 cell	NWXwSGloT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX;RPJc6UW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?=	MlPrV2FPT0WU
human T47D cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVXsW4J7UW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2=	MWLTRW5ITVJ?
A549 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWrJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O	Mmf1V2FPT0WU
PC-14 cell	M3jXU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlnLTY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK0Mlc{KG6P	NFjkV\|FUSU6JRWK=
A704 cell	M4LWbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV7NN292UW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPDVibl2=	NI\nXoRUSU6JRWK=
MCF7 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEH6SmpKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?=	Ml3mV2FPT0WU
PC3 cells	NYDadW9kTnWwY4Tpc44h[XO\|YYm=	Moq0TY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN\|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF\|IN88US=>	NInPTGszOTN2MU[3OS=>
F-36P cells	NITaeppRem:uaX\ldoF1cW:wIHHzd4F6	NX3lZYR1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?=	MknQNlE{PDF4N{W=
OCI-AML2 cells	M4jRXnBzd2yrZnXyZZRqd25iYYPzZZk>	M3HDUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2=	M4HE[VIyOzRzNke1
K562 cells	NXfLbIxVWHKxbHnm[ZJifGmxbjDhd5NigQ>?	NHLINJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOsJGlEPTB;MUig{txO	MoL3NlE{PDF4N{W=

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: Hs294T, HSB2, and Ramos Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM Incubation Time: 18, or 24 hours Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit. (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors Formulation: Dissolved in DMSO, and diluted in saline Dosages: ~100 mg/kg Administration: Intravenous injection (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

+ Expand

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01280786	Unknown status	Acute Myeloid Leukemia	Synta Pharmaceuticals Corp.	January 2011	Phase 1
NCT00888615	Active not recruiting	Fallopian Tube Clear Cell Adenocarcinoma\|Fallopian Tube Endometrioid Adenocarcinoma\|Fallopian Tube Mucinous Adenocarcinoma\|Fallopian Tube Serous Adenocarcinoma\|Fallopian Tube Transitional Cell Carcinoma\|Ovarian Brenner Tumor\|Ovarian Clear Cell Adenocarcinoma\|Ovarian Endometrioid Adenocarcinoma\|Ovarian Mucinous Adenocarcinoma\|Ovarian Seromucinous Carcinoma\|Ovarian Serous Adenocarcinoma\|Ovarian Transitional Cell Tumor\|Primary Peritoneal Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma\|Undifferentiated Fallopian Tube Carcinoma\|Undifferentiated Ovarian Carcinoma	Gynecologic Oncology Group\|National Cancer Institute (NCI)	December 2010	Phase 2
NCT00827203	Suspended	Metastatic Solid Tumors	Synta Pharmaceuticals Corp.	January 2009	Phase 1
NCT00808418	Completed	Prostate Cancer	Synta Pharmaceuticals Corp.	November 2008	Phase 1
NCT00522834	Terminated	Melanoma	Synta Pharmaceuticals Corp.	August 2007	Phase 3
NCT00087997	Completed	Soft Tissue Sarcoma	Synta Pharmaceuticals Corp.	July 2004	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 6 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 6 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)